Gyre Therapeutics (NASDAQ:GYRE) Shares Down 7.8% – Time to Sell?

Posted by Thomas Dobrow on Nov 15th, 2024

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) traded down 7.8% during trading on Friday . The stock traded as low as $12.65 and last traded at $12.76. 26,772 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 68,420 shares. The stock had previously closed at $13.84.

Gyre Therapeutics Trading Down 2.2 %

The business’s 50 day moving average price is $13.81 and its 200-day moving average price is $13.02.

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The business had revenue of $25.23 million during the quarter. Gyre Therapeutics had a negative return on equity of 119.54% and a negative net margin of 60.75%. Research analysts predict that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC purchased a new stake in shares of Gyre Therapeutics during the 3rd quarter worth approximately $47,000. Rhumbline Advisers purchased a new stake in Gyre Therapeutics during the second quarter worth $123,000. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth $166,000. Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at about $218,000. Finally, WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the 2nd quarter valued at about $220,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.